Deep learning detects acute myeloid leukemia and predicts NPM1 mutation status from bone marrow smears
Jan‐Niklas Eckardt(Klinik und Poliklinik für Psychotherapie und Psychosomatik), Martin Bornhäuser(Technische Universität Dresden), Michael Krämer(University Hospital Carl Gustav Carus), Tim Schmittmann, Karsten Wendt, Christoph Röllig(University Hospital Carl Gustav Carus), Anas Shekh Sulaiman(University Hospital Carl Gustav Carus), Jan Moritz Middeke(Fresenius (Germany)), Sebastian Riechert, Ulrich S. Schuler(University Hospital Carl Gustav Carus), Frank Kroschinsky(University Hospital Carl Gustav Carus), Johannes Schetelig(University Hospital Carl Gustav Carus), Katja Sockel(Innsbruck Medical University), Christian Thiede(University Hospital Carl Gustav Carus)
Cited by 118
Related Papers
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
|Blood|2022|3k
Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a <i>FLT3</i> Mutation
|New England Journal of Medicine|2017|2.2k
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party
|Blood|2018|1k
The future landscape of large language models in medicine
|Communications Medicine|2023|937